Form 4: Acrivon Therapeutics COO, Eric Devroe, Reports Share Disposal for Tax Obligations
SEC Form 4 Filing
Eric Devroe, Chief Operating Officer of Acrivon Therapeutics, reports the disposal of 613 common stock shares to cover tax withholding requirements.
Summary
- On May 14, 2024, Eric Devroe, the Chief Operating Officer of Acrivon Therapeutics, Inc. (ACRV), disposed of 613 shares of common stock.
- The disposal was executed to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
- The shares were disposed of at a price of $8.36 per share.
- Following the transaction, Devroe directly owns 59,097 shares of Acrivon Therapeutics, Inc.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock transactions for tax purposes, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like the COO in this case, trade their company's stock. These filings provide transparency to the market regarding the transactions of company executives and directors.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it is a routine disposal of shares to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 05/14/2024 | Date of transaction: Eric Devroe disposed of shares. |
| 05/16/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.